Clinical Trials Logo

Filter by:
NCT ID: NCT05527028 Recruiting - Aging Clinical Trials

OT Directed Services in Long-term Care in Ontario

OTLTC
Start date: July 1, 2022
Phase: N/A
Study type: Interventional

In long-term care, staff provide help to residents with bathing, dressing, eating, walking, toileting, transferring, and moving in bed. Some residents can do more for themselves than others. This study will compare two groups of residents who require the same level of help from staff. Over eight weeks, one group will receive occupational therapy services provided by OT students and the other group will not. After the eight weeks, the level of help that each group of people requires will be looked at to see if there are any differences.

NCT ID: NCT05526937 Completed - Blood Sugar Clinical Trials

The Effect of Sprouting of Wheat on Postprandial Glycemic and Satiety Responses of Wheat Bread Products

Start date: October 18, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to investigate the effect of inclusion of 50% sprouted wheat wholemeal in a bread recipe on the postprandial glycemic and satiety responses, as well as on appetite-related sensations and acceptability of the developed products relative to a product made with a similar unsprouted wheat recipe.

NCT ID: NCT05526560 Active, not recruiting - Clinical trials for Mitral Valve Insufficiency

Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve

MOMENTIS
Start date: January 11, 2023
Phase:
Study type: Observational

Collect real-world data on acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in subjects requiring replacement of their native or prosthetic mitral valve with or without concomitant procedures.

NCT ID: NCT05526521 Recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

Start date: August 25, 2022
Phase: Phase 3
Study type: Interventional

This is a multicenter, single-arm, 24-week treatment, Phase 3 study. The purpose of this study is to investigate the PK and safety of dupilumab in children diagnosed with CSU who remain symptomatic despite the use of H1-antihistamine treatment. Study details include: Screening: 2 to 4 weeks; The treatment duration will be 24 weeks; Follow-up period: 12 weeks; The study duration will be 38 to 40 weeks (including screening and follow-up); The number of study visits will be 6.

NCT ID: NCT05526495 Recruiting - Surgery Clinical Trials

Reducing Low-Value Preoperative Investigations in Patients Undergoing Low Risk Surgery

Pre-Op
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate if a multi-component behavioral intervention given to anesthesiologists and surgeons is associated with decreasing low value preoperative testing orders in patients undergoing low risk surgery. The objectives of this trial are to evaluate a) the overall rate of low-value preoperative test (electrocardiogram and chest X-ray) in patients undergoing low risk surgery, b) to conduct an economic and c) process evaluation of the implementation The investigators will assess these outcomes in a sample of 22 Hospitals in Ontario, Canada.

NCT ID: NCT05525780 Completed - Alzheimer Disease Clinical Trials

Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Tablets in Healthy Male Volunteers

Start date: August 26, 2022
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety and tolerability of single dose of GB-5001 (donepezil) IM depot in healthy male volunteers. And, it is to predict the multiple-dose pharmacokinetics based on the single-dose pharmacokinetics of GB-5001 IM depot and the oral Aricept® (donepezil hydrochloride) tablet by PK modeling.

NCT ID: NCT05525520 Active, not recruiting - Pruritus Clinical Trials

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

PACIFIC
Start date: October 6, 2022
Phase: Phase 2
Study type: Interventional

This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC)

NCT ID: NCT05525416 Completed - Vasodilation Clinical Trials

Sex Differences in Sympathetic Vascular Reactivity at High Altitude

Start date: July 28, 2022
Phase: N/A
Study type: Interventional

This study aims to investigate sex differences in blood pressure control associated with exposure to acute hypoxia (low oxygen), and short term acclimatization to hypoxia at high altitude.

NCT ID: NCT05524883 Recruiting - Clinical trials for Duchenne Muscular Dystrophy (DMD)

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

DELIVER
Start date: August 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the safety, tolerability, and dystrophin protein levels in muscle tissue following multiple intravenous (IV) doses of DYNE-251 in participants with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The study consists of 3 periods: a multiple-ascending dose (MAD) / placebo-controlled period (24 weeks), an open-label period (24 weeks) and a long-term extension period (96 weeks).

NCT ID: NCT05523869 Recruiting - Clinical trials for Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment

Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment With Proliferative Vitreoretinopathy

TOPO-RD
Start date: February 23, 2023
Phase: Phase 2
Study type: Interventional

Intravitreal topotecan has anti-inflammatory, anti-proliferative and anti-fibrotic activity that we hypothesize may exhibit high efficacy for the treatment of proliferative vitreoretinopathy (PVR) in patients with rhegmatogenous retinal detachment (RRD). A high efficacy for intravitreal topotecan has been exhibited in cell cultures of PVR. At the same time, intravitreal topotecan has been routinely used in the treatment of vitreous seeds from retinoblastoma. At doses of 5-30 micrograms per injection, no adverse events have been reported with the use of intravitreal topotecan. Therefore, the current prospective matched phase II trial aims to investigate the efficacy and safety of intravitreal topotecan for severe PVR in patients with RRD.